Scholarlink

Background <p>Although platelet-rich fibrin (PRF) is a biological material with high regenerative potential, its rapid resorption limits its clinical effectiveness. Albumin-platelet-rich fibrin (Alb-PRF), developed in recent years, exhibits prolonged resorption time. The aim of this study was to evaluate the clinical, radiographic, and biochemical effects of Alb-PRF application into periodontal pockets following non-surgical periodontal therapy (NSPT) using a randomized split-mouth design.</p> Methods <p>This study included 23 patients diagnosed with Stage III Grade B periodontitis. Following completion of NSPT, Alb-PRF was applied into periodontal pockets at the test sites. Gingival crevicular fluid (GCF) samples were collected on days 7, 14, and 21. Clinical periodontal parameters were recorded at baseline, 3 and 6 months, and radiographs were obtained at baseline and at 6 months. Levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), transforming growth factor-β (TGF-β), and basic fibroblast growth factor (b-FGF) in GCF were analyzed using enzyme-linked immunosorbent assay (ELISA). Primary outcome measures included changes in probing depth (PD), clinical attachment loss (CAL), and GCF growth factor levels, while secondary outcome measures included changes in plaque index, gingival index (GI), bleeding on probing, gingival recession, and radiographic parameters.</p> Results <p>GI, PD, and CAL were significantly lower at test sites at 3 months (<i>p</i> &lt; 0.01). However, these differences were not maintained at the 6-month follow-up. Radiographic defect depth and bone loss percentage were significantly lower at test sites at 6 months (<i>p</i> &lt; 0.01). Transforming growth factor-β values were significantly higher at test sites at all subsequent time points (<i>p</i> &lt; 0.01, <i>p</i> &lt; 0.01, and <i>p</i> &lt; 0.05, respectively).</p> Conclusions <p>Alb-PRF may represent a beneficial adjunctive approach for early periodontal healing following NSPT; however, further studies are needed to clarify the sustainability of these effects over time.</p> Trial registration <p>ClinicalTrials.gov NCT07363135, registered on 15 January 2026 (retrospectively registered).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of albumin-platelet-rich fibrin as an adjunct to non-surgical periodontal therapy in patients with periodontitis: a randomized controlled clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Erkan Özcan,
  • Berrak Ulu Emir,
  • Emre Avcı,
  • Savaş Özarslantürk,
  • Şeyma Çardakcı Bahar

摘要

Background

Although platelet-rich fibrin (PRF) is a biological material with high regenerative potential, its rapid resorption limits its clinical effectiveness. Albumin-platelet-rich fibrin (Alb-PRF), developed in recent years, exhibits prolonged resorption time. The aim of this study was to evaluate the clinical, radiographic, and biochemical effects of Alb-PRF application into periodontal pockets following non-surgical periodontal therapy (NSPT) using a randomized split-mouth design.

Methods

This study included 23 patients diagnosed with Stage III Grade B periodontitis. Following completion of NSPT, Alb-PRF was applied into periodontal pockets at the test sites. Gingival crevicular fluid (GCF) samples were collected on days 7, 14, and 21. Clinical periodontal parameters were recorded at baseline, 3 and 6 months, and radiographs were obtained at baseline and at 6 months. Levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), transforming growth factor-β (TGF-β), and basic fibroblast growth factor (b-FGF) in GCF were analyzed using enzyme-linked immunosorbent assay (ELISA). Primary outcome measures included changes in probing depth (PD), clinical attachment loss (CAL), and GCF growth factor levels, while secondary outcome measures included changes in plaque index, gingival index (GI), bleeding on probing, gingival recession, and radiographic parameters.

Results

GI, PD, and CAL were significantly lower at test sites at 3 months (p < 0.01). However, these differences were not maintained at the 6-month follow-up. Radiographic defect depth and bone loss percentage were significantly lower at test sites at 6 months (p < 0.01). Transforming growth factor-β values were significantly higher at test sites at all subsequent time points (p < 0.01, p < 0.01, and p < 0.05, respectively).

Conclusions

Alb-PRF may represent a beneficial adjunctive approach for early periodontal healing following NSPT; however, further studies are needed to clarify the sustainability of these effects over time.

Trial registration

ClinicalTrials.gov NCT07363135, registered on 15 January 2026 (retrospectively registered).